Nucleophosmin contributes to vascular inflammation and endothelial dysfunction in atherosclerosis progression

Nucleophosmin contributes to vascular inflammation and endothelial dysfunction in atherosclerosis progression

Journal Pre-proof Nucleophosmin contributes to vascular inflammation and endothelial dysfunction in atherosclerosis progression Caijun Rao, PhD, Baoqi...

2MB Sizes 0 Downloads 34 Views

Journal Pre-proof Nucleophosmin contributes to vascular inflammation and endothelial dysfunction in atherosclerosis progression Caijun Rao, PhD, Baoqing Liu, PhD, Dandan Huang, PhD, Ru Chen, MD, Kai Huang, PhD, Fei Li, MD, Nianguo Dong, PhD PII:

S0022-5223(19)32776-X

DOI:

https://doi.org/10.1016/j.jtcvs.2019.10.152

Reference:

YMTC 15318

To appear in:

The Journal of Thoracic and Cardiovascular Surgery

Received Date: 7 June 2019 Revised Date:

15 October 2019

Accepted Date: 15 October 2019

Please cite this article as: Rao C, Liu B, Huang D, Chen R, Huang K, Li F, Dong N, Nucleophosmin contributes to vascular inflammation and endothelial dysfunction in atherosclerosis progression, The Journal of Thoracic and Cardiovascular Surgery (2020), doi: https://doi.org/10.1016/j.jtcvs.2019.10.152. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Copyright © 2019 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery

Nucleophosmin contributes to vascular inflammation and endothelial dysfunction in atherosclerosis progression Caijun Rao,PhD1,2,3,a, Baoqing Liu, PhD4,a, Dandan Huang, PhD2,3,, Ru Chen, MD2,3, Kai Huang, PhD2,3,*, Fei Li, MD4,* , Nianguo Dong, PhD4 1

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science

and Technology, Wuhan, China. 2

Clinical Center for Human Genomic Research, Union Hospital, Tongji Medical College, Huazhong

University of Science and Technology, Wuhan, China 3

Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science

and Technology, Wuhan, China 4

Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University

of Science and Technology, Wuhan, China a

Caijun Rao, Baoqing Liu contributed equally as first authors.

*Correspondence: Fei Li, MD, Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China, E-mail: [email protected] Co-Corresponding author: Kai Huang, FACC, PhD, Department of cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China, E-mail: [email protected]

Word account for the abstract: 248 Word account for the manuscript: 3665 Number of references: 35 Number of figures: 6 Number of supplemental figures/tables: 9 Conflict of interest: none declared. Funding: This study was supported by the National Natural Science Foundation of China (81670351, 81300173, 81570405 and 81670241). Central Picture Legend NPM accelerated the progression of atherosclerosis via NF-κB pathway. Central Message Nucleophosmin was enriched in human atherosclerotic plaque. Nucleophosmin aggravated atherosclerosis through promoting NF-κB pathway mediated vascular inflammation and endothelial dysfunction. Prospective Statement Nucleophosmin has been involved in the pathogenesis of many other diseases, however, its role in atherosclerosis remains unknown. This study provided novel evidence that nucleophosmin promoted atherosclerosis by inducing vascular inflammation and endothelial dysfunction through NF-κB signaling pathway, and suggested that nucleophosmin may be a promising target for atherosclerosis prevention and treatment. Video Legend This study uncovered a novel role of nucleophosmin in the progression of atherosclerosis. We found the level of nucleophosmin was higher in human atherosclerotic plaques than that in normal artery. Knockdown of nucleophosmin in vivo decreased macrophage infiltration, suppressed plaque formation and improved plaque stability in ApoE-/- mice. In vascular endothelial cells, nucleophosmin could bind with NF-κB p65, promote its intra-nuclear translocation and enhance the expression of

downstream target genes. Although this study has some limitations, we still believe that our findings are of general interest to the readers.

1

Nucleophosmin contributes to vascular inflammation and endothelial dysfunction in

2

atherosclerosis progression

3

Abstract

4

Objective: It was uncertain whether Nucleophosmin (NPM) participated in cardiovascular disease. The

5

present study aims to investigate the role and underlying mechanisms of NPM in atherosclerosis.

6

Methods: :Levels and location of NPM in human carotid atherosclerotic plaques and healthy controls

7

were detected by Real-time PCR, immunoblots and immunofluorescence. Atherosclerotic prone ApoE-/-

8

mice were fed with western diet for 16 weeks as in vivo model. Human primary umbilical vein

9

endothelial cells (HUVECs) were cultured as in vitro model.

10

Results: Compared with controls, we found that NPM level in human carotid atherosclerotic plaques

11

was more than twice as high as in normal arteries, which mainly localized in endothelial cells. In vivo,

12

adenovirus containing NPM shRNA attenuated atherosclerotic lesion and promoted plaque stabilization

13

in western diet-fed ApoE-/- mice by reducing vascular inflammation, maintaining endothelial function

14

and decreasing macrophage infiltration. Furthermore, NPM knockdown decreased Nuclear factor-κB

15

(NF-κB) p65 phosphorylation. In cultured HUVECs, palmitic acid (PA) increased the protein levels of

16

NPM, and induced the expression of inflammatory cytokines and monocyte adhesion, while NPM

17

knockdown attenuated this effect. In HUVECs, NPM protein physically interacted with NF-κB p65

18

subunit and promoted its nuclear transposition. NPM could also increase the transcriptional activity of

19

NF-κB p65 promoter and enhance its binding to target genes including IL-1β, IL-6, ICAM-1 and

20

E-selectin.

21

Conclusions: These data provided novel evidence that NPM promoted atherosclerosis by inducing

22

vascular inflammation and endothelial dysfunction through NF-κB signaling pathway, and suggested 1

23

that NPM may be a promising target for atherosclerosis prevention and treatment.

24

Keywords: Nucleophosmin; NF-κB; Vascular inflammation; Endothelial dysfunction; Atherosclerosis

2

25

Introduction

26

Atherosclerosis is a chronic vascular inflammatory disease which leads to some life-threatening

27

complications, such as myocardial infarction and stroke. The increasing prevalence and mortality results

28

in loss of productive life and death worldwide in recent years.

29

risk factors is referred as a pathogenic sine qua non for atherosclerotic cardiovascular disease.

30

Following endothelial impairment, circulating monocytes were then recruited to the intima and

31

differentiated to macrophages, which internalized modified lipoproteins to become foam cells (the

32

hallmark of early lesions). 4

33

1-3

Endothelial dysfunction induced by

It is noteworthy that Nuclear factor-κB (NF-κB) appears to play a pivotal role in the

34

pro-inflammatory activation of endothelium in atherogenesis.

35

transcription factor that can be activated by a variety of the pathophysiologic stimuli, resulting the

36

regulation of multiple effector proteins associated with atherosclerosis such as inflammatory

37

cytokines, chemokines, adhesion molecules and cell death signals. 7

5, 6

NF-κB is a pleiotropic

38

Nucleophosmin (NPM, B23, Numatrin or NO38) is a widely expressed and critical

39

phosphoprotein in the nucleoplasmin family. 8 NPM mainly exists in the nucleolus where it plays

40

its major functions, while it can also convert back and forth between the nucleus and the

41

cytoplasm.9, 10 NPM has been implicated in a number of pathways including ribosome biogenesis,

42

chromatin remodeling, apoptosis and cell differentiation, participating several human

43

malignancies.11, 12

44

More recently, emerging evidence suggests that NPM controls DNA transcription through

45

interaction with different transcription factors. NPM can either contribute to transcriptional activation,

46

as in the report of Myc-interacting zinc finger protein 1 (Miz1)13, androgen receptor14, ribosomal 3

47

genes15, c-Myc and Nuclear factor-κB (NF-κB)16, or to repression, as for the activating protein

48

transcription factor 2α (AP2α)17. These studies all point to the potentially vital function of NPM in

49

regulating gene expression in the transcription level.

50

Nevertheless, little is known about the role and mechanisms of NPM in arterial pathophysiology.

51

In this study, we intended to investigate the role and underlying mechanisms of NPM in exacerbating

52

vascular inflammation and endothelial dysfunction in atherosclerosis progression

53

4

54 55 56

Materials and Methods Expanded methods are available in supplemental data. Clinical Samples Collection

57

All the studies involving humans complied with the declaration of Helsinki and were approved by

58

the Ethics Committee of Huazhong University of Science and Technology. Written informed consent

59

was obtained from all participants before surgery. Carotid atherosclerotic plaque specimens were

60

explanted from patients undergoing carotid endarterectomy. Control specimens came from normal aorta

61

of patients without atherosclerosis during aortic valve replacement.

62

Animal Studies

63

All animal studies followed the guidelines of the Animal Care and Use Committee of Huazhong

64

University of Science and Technology. Eight-week-old male ApoE-/- mice were randomly devided into

65

4 groups: ApoE-/- mice fed with a chow diet or western diet for 16 weeks treated with Ad-shNC or

66

Ad-shNPM respectively (n=18 for each group). Four weeks before sacrificed, mice were injected with

67

5×108 plaque-forming unites (5×108 pfu/mouse) either Ad-shNC or Ad-shNPM adenovirus via the tail

68

vein every two weeks. Mice were housed individually under a 12h light/12h dark cycle and sacrificed

69

by cervical dislocation.

70

NPM Knockdown in Vivo and in Vitro

71

Adenovirus containing specifically designed shRNA was used to knock down NPM expression in

72

animal experiments. siRNA was transfected into HUVECs to knockdown NPM expression in cellular

73

experiments..

74

Cell Culture and Treatment

75

Human primary umbilical vein endothelial cells (HUVECs) were isolated from umbilical veins by 5

76

using 0.1% collagenase I (Sigma-Aldrich) and cultured in specific endothelial cell medium (ECM)

77

(Sciencell) with 10% fetal bovine serum (FBS) according to the reagent manufacturer's instructions.

78

HUVECs between passages 3 to 8 were used and treated with palmitic acid (PA) as in vitro model.

79

Adhesion Assay

80

Adhesion assay was performed using Endothelial Cell Adhesion Assay Kit (ECM645; Bioscience

81

Research Reagents) according to the manufacturer's instructions.

82

Immunoprecipitation Assay

83

Immunoprecipitation assay (IP) was carried out as described in previous studies. 500 µg of total

84

proteins were incubated with NF-κB p65 antibody (8242S; CST) and NPM antibody (ab10530; Abcam)

85

at 4 degree overnight with protein A+G magnetic beads (Millipore). The immunoprecipitates were

86

washed and centrifuged 4 times with lysis buffer, following by western blot analysis. Immunoglobulin

87

G (IgG) from the same species was used as negative control.

88

Gene Overexpression

89

Human NPM plasmid was obtained from ORIGENE (RC203841), full length of human NPM

90

coding sequence was constructed in a functional mammalian expression vector pCMV6. pCMV6-Entry

91

vector was used as a negative control (Entry vector). The cultured HEK293 cells and HUVECs were

92

transfected with plasmids using lipofectamine 2000 (Invitrogen) for 24 hours before subsequent

93

experiments.

94

Luciferase Assay

95

By using the One Step Cloning Kit (C112-02; Vazyme Biotech), NF-κB luciferase reporter plasmid

96

was purchased from Tsingke Biotechnology, promoters of ICAM-1, VCAM-1, E-selectin, and P-selectin

97

were assembled into pGL3.0 vector (Promega). Primers used above were listed in Supplemental Table 3. 6

98

HEK293 cells were transfected with an internal control plasmid (pRL-TK; Promega) and plasmids

99

containing other promoter regions simultaneously. Luciferase activity were detected with the Dual

100

Luciferase Reporter Assay Kit (Promega).

101

Chromatin Immunoprecipitation Assay

102

Chromatin immunoprecipitation assay (ChIP) was performed by ChIP assay kit (Millipore)

103

according to the manufacturer’s instructions. Using PCR to detect DNA samples enriched by NF-κB

104

p65 antibody (8242S; CST) to test whether the downstream target genes have changed. Rabbit IgG

105

antibody was performed as negative control. Primers used in ChIP assay were shown in Supplemental

106

Table 4.

107

Statistical Analysis

108

For the data of human characteristics, continuous variables were shown as mean ± SD when it was

109

normally distributed or median (interquartile range) when it was not and evaluated by Student’s t test or

110

nonparametric test when appropriate, categorical variables were presented as percentages and compared

111

between groups with chi-square tests.18

112

For the results of animal and cellular experiments, data were presented as the mean ± SD,

113

statistical differences were evaluated by unpaired Student’s t-test between two groups or one-way

114

analysis of variance (ANOVA) for multiple group comparison. Bonferonni corrections were made

115

for the multiple testing. All analysis was performed with SPSS 23.0, P<0.05 was characterized as

116

statistically significant.

7

117

Results

118

NPM was enriched in human atherosclerotic plaque

119

To explore the involvement of NPM in atherosclerosis, we first examined the level of NPM in 12

120

carotid atherosclerotic plaques and 12 human healthy arteries. The demographic characteristics of

121

patients were summarized in Supplemental Table 1. The level of NPM mRNA was more than twice as

122

high as that in normal arteries, immunoblots also indicated that the protein level of NPM was elevated

123

in plaque tissues (Figure 1A and 1B). To determine the cellular localization of NPM, we performed dual

124

immunofluorescent staining of human carotid atherosclerotic plaques using antibodies against NPM and

125

CD31 (marker of endothelial cells), CD68 (marker of macrophages) or α-SMA (marker of smooth

126

muscle cells). As shown in Figure 1C, NPM predominantly co-localized with CD31 positive cells,

127

suggesting that NPM was mainly expressed in VECs.

128

Inhibition of NPM attenuated endothelial dysfunction and atherosclerosis in ApoE-/-mice

129

To evaluate the effect of NPM on atherosclerosis in vivo, we generated recombinant adenovirus

130

containing NPM shRNA (shNPM) and injected it into ApoE-/- mice via tail vein. As confirmed in Figure

131

2A and 2B, Ad-shNPM inhibited the transcriptional and translational expression of NPM by 65.2% in

132

the murine aorta. Oil Red O staining showed that Ad-shNPM decreased lesion area at aortic sinus by

133

45.1% compared to the control treated with Ad-shNC in western diet-fed ApoE-/- mice, while none

134

significant beneficial effect was observed in mice fed with chow diet (Figure 2C). Likewise, NPM

135

knockdown markedly reduced atherosclerotic plaque formation (decreased by 51.3% compared to

136

Ad-shNC-treated mice, Figure 2D). Knockdown of NPM also improved atherosclerotic plaque stability,

137

as shown in Figure 2E, Ad-shNPM-treated mice exhibited smaller necrotic core area, thicker fibrous

138

caps, less elastic fiber breaks, as well as decreased macrophage infiltration. Furthermore, Ad-shNPM 8

139

suppressed NF-κB p65 phosphorylation and decreased the protein level of VCAM-1, ICAM-1,

140

E-selectin, indicating that knockdown of NPM attenuated endothelial dysfunction and inflammation in

141

western diet-fed ApoE-/- mice (Figure 2F).

142

Knockdown of NPM suppressed the inflammatory responses in HUVECs

143

To investigate the role of NPM in endothelial function, we knocked down NPM in HUVECs by

144

siRNA. RT-PCR and Western blot showed that NPM siRNA efficiently decreased the expression of

145

NPM (Supplemental Figure 3A and 3B). To explore whether NPM was involved in the regulation of

146

endothelial cell inflammatory reactions, we tested mRNA levels of cytokines and adhesion molecules in

147

HUVECs stimulated by palmitic acid (PA)19 with or without NPM knockdown (Figure 3A). Depletion

148

of NPM with siRNA notably reduced the levels of IL-1β, IL-6 and TNF-α in the supernatants of

149

HUVECs incubated with PA (Figure 3B). We further characterized the effect of NPM on the expression

150

adhesion molecules. We measured the expression of ICAM-1, VCAM-1, and E-selectin by western blot

151

analysis, and showed that knockdown of NPM suppressed the expression of all these molecules in

152

varying degrees (Figure 3C). After that, we generated endothelial cell monolayer adhesion assay using

153

immunofluorescence technique. Consistent with the above results, NPM knockdown could significantly

154

reduce the number of peripheral blood monocytes attached to PA-activated endothelial cell monolayers

155

(Figure 3D).

156

NPM physically interacted with NF-κ κB p65 subunit and promoted its activation

157

To uncover the underlying mechanism of the above observations, we explored whether NF-κB

158

pathway, a crucial pro-inflammatory transcription factor, was involved in the process. The

159

phosphorylation and nuclear translocation of NF-κB p65 subunit is indispensable for its transcriptional

160

activation, we measured the expression level of phospho-p65 (p-p65) to evaluate the activation status of 9

161

NF-κB not only in total protein but also in nuclear extract and cytoplasmic extract respectively (Figure

162

4A and 4B). Immunofluorescent staining showed that PA promoted nucleus translocation of p65, which

163

could be prevented by NPM siRNA (Figure 4C). To investigate how NPM modulated NF-κB

164

transcriptional activity, we hypothesized that NPM could function as a transcriptional co-activator that

165

interacted with NF-κB via physical binding. We immunoprecipitated NF-κB p65 in untreated cells, and

166

detect the bound form of NPM with western blot. Conversely, immunoprecipitation of NPM resulted in

167

the co-precipitation of NF-κB p65. Furthermore, treatment with PA strengthened their interaction with

168

each other in HUVECs (Figure 4D). PA treatment and NPM over-expression by transfecting NPM

169

plasmid significantly augmented the promoter activity of NF-κB p65, which could also be inhibited by

170

NPM siRNA or NF-κB inhibitor PDTC20-22 (Figure 4E).

171

NPM enhanced the transcriptional activity of NF-κ κB to its downstream target genes

172

NF-κB regulates gene expression through binding to specific sites in the promoter of target genes.

173

We examined the promoter activities of the adhesion molecules includingICAM-1, VCAM-1, E-selectin,

174

and P-selectin. PA treatment and NPM over-expression significantly up-regulated the luciferase

175

activities of all promoters except for ICAM-1, whereas the increased luciferase activity could be

176

reduced by NF-κB inhibitor PDTC (Figure 5A). To further determine the influence of NPM on the DNA

177

binding activity of NF-κB, chromatin immunoprecipitation (ChIP) experiments was performed. NPM

178

over-expression could enhance more NF-κB binding to its downstream gene promoters, including IL-1β,

179

IL-6, ICAM-1 and E-selectin (Figure 5B).

10

180

Discussion

181

Currently, little is known about NPM involvement in the progression of atherosclerosis. The

182

present study showed that NPM was enriched in human atherosclerotic plaque and depletion of NPM

183

attenuated the atherosclerotic lesions in ApoE-/- mice fed with western diet. This effect was

184

accompanied by reduced NF-κB activation as well as macrophage infiltration and adhesion molecules

185

expression. In vitro studies showed that NPM knockdown significantly inhibited inflammatory

186

cytokines production (including IL-1, IL-6 and TNF-α) and adhesion molecules (including ICAM-1,

187

VCAM-1 and E-selectin) as well as NF-κB p65 intranuclear translocation in cultured HUVECs

188

stimulated by PA. Furthermore, NPM modulated NF-κB transcriptional activity via physical interaction

189

with p65 subunit. To our knowledge, the novel findings provided the first evidence that

190

pro-inflammatory effects induced by NPM/NF-κB interaction in VECs contributed to the development

191

and progression of atherosclerosis.

192

NPM is an important nucleocytoplasmic shuttling protein which has been reported to participate in

193

metabolic pathways, DNA repair pathways and regulating apoptosis. NPM malfunction such as

194

overexpressed, mutated, rearranged or deleted has been described in a varieties of cancers including

195

lymphoma, acute myeloid leukemia, breast cancer and gastric cancers.23 However, emerging evidence

196

suggests that NPM-mediated nucleolar stress is involved in cardiovascular disease such as myocardial

197

infarction and hypertension.24, 25 tudies also linked NPM to the onset of atherosclerosis. NPM mRNA

198

expression was increased in carotid arteries of aged rats.26 Oxidized low density lipoprotein decreased

199

human VECs proliferation through NPM dephosphorylation.27 Consistent with previous studies, our

200

findings further provided a more robust evidence that NPM mRNA and protein levels were increased in

201

human atherosclerotic plaques and mainly localized in vascular endothelial cells. In addition, 11

202

knockdown of NPM in vivo attenuated atherosclerotic lesions in western diet-fed ApoE-/- mice.

203

Endothelial cells not only function as a barrier but also can undergo a dramatic transition in their

204

phenotype in response to injury or other biological stimuli including pathogen-associated molecular

205

patterns (PAMPs) and other damage-associated

206

pro-inflammatory activation resulted in the expression of leukocyte adhesion molecules, such as

207

ICAM-1, VCAM-1 and E-selectin, which selectively recruited circulating monocytes into intima, where

208

they differentiated into macrophages and internalize modified lipoproteins to become foam cells. In our

209

study, NPM knockdown inhibited the production of inflammatory cytokines and adhesion molecules in

210

HUVECs, thus significantly reduced attachment of monocytes to endothelial cells. In addition,

211

knockdown of NPM in vivo also resulted in decreased expression of ICAM-1, VCAM-1 and E-selectin

212

as well as reduced macrophage infiltration.

molecular patterns (DAMPs). Endothelial

213

Highly unstable plaques are thought to be fast-growing and accompanied with superimposed

214

thrombosis, eventually leading to acute adverse cardiovascular events.28 Typical features of the

215

vulnerable plaques include massive infiltration of inflammatory cells, and a large necrotic core with thin

216

fibrous cap.29 Compared with control, Ad-shNPM treated mice turned out to have thicker fibrous caps,

217

smaller central necrotic areas and less elastic fiber breaks, suggesting that in addition to the reduction in

218

lesion size, the plaque stability was also greatly improved. From the above, NPM overexpression

219

probably aggravated atherosclerotic lesion and plaque unstability through inducing endothelial

220

pro-inflammation change. However, these indicators have their limitation and can only indirectly reflect

221

plaque stability.

222

more properly.

223

30-32

Further studies are needed to investigate the effect of NPM on plaque stability

Nuclear factor-κB (NF-κB) mediated pro-inflammatory signaling pathway plays a crucial role in 12

224

endothelial dysfunction. Our findings demonstrated knockdown of NPM inhibited PA-induced NF-κB

225

p65 subunit phosphorylation and intra-nuclear translocation. Furthermore, we found physical interaction

226

between NPM and NF-κB p65 subunit. NPM also enhanced p65 promoter activity. Pretreatment with

227

NF-κB inhibitor decreased adhesion molecules promoter activity induced by NPM over expression. All

228

these results demonstrated that NF-κB activation might be responsible for the detrimental role of NPM

229

in atherosclerosis. Interestingly, recent studies suggested that NPM level tended to be upregulated

230

during aging heart, and SIRT1 may prevent NPM-induced NF-κB activation.

231

warranted to clarify the role of NPM in regulation of pathophysiological conditions associated with

232

arterial aging.

26

Further studies are

233

In summary, the present study uncovered a previously unrecognized role of NPM in exacerbating

234

endothelial inflammation during the progression of atherosclerosis in ApoE-/- mice. NPM knockdown

235

abrogated PA-induced expression of inflammatory cytokines as well as adhesion molecules in cultured

236

HUVECs and reduced atherosclerosis plaque formation in western diet-fed ApoE

237

protective effects were probably mediated via inhibition of NF-κB signaling pathway (Figure 6). All the

238

above-mentioned suggested NPM may be a promising target for slowering atherosclerosis, stabilizing

239

plaque and reducing associated adverse events.

240

Study limitations

-/-

mice. These

241

Some limitations existed in our work. One was that we did not examine the effect of NPM

242

knockdown on the metabolism of serum lipids in ApoE -/- mice. The other was that we performed all the

243

works on male mice, whether NPM made sense in female animals remained unknown, for male and

244

female differed in the development of atherosclerosis.33,

245

(VSMCs) can also express ICAM-1 and VCAM-1 in atherosclerosis35, whether NPM can directly 13

34

Besides, vascular smooth muscle cells

246

regulate SMC function is also unknown. Furthermore, although the specimens were ample enough to

247

study, the result would be more robust if increasing the sample size for some comparison.

248

Conflict of interest: none declared.

249

Funding: This study was supported by the National Natural Science Foundation of China (81670351,

250

81300173, 81570405 and 81670241).

14

251

References

252

1.

253 254

Libby

P.

Inflammation

in

atherosclerosis.

Arterioscler

Thromb

Vasc

Biol.

2012;32:2045-2051 2.

255

Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488

256

3.

Williams KJ, Tabas I. Atherosclerosis and inflammation. Science. 2002;297:521-522

257

4.

Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler

258 259

Thromb Vasc Biol. 2007;27:2292-2301 5.

260 261

2002;2:725-734 6.

262 263

7.

Baker RG, Hayden MS, Ghosh S. Nf-kappa b, inflammation, and metabolic disease.

Cell metabolism. 2011;13:11-22 8.

266 267

Tak PP, Firestein GS. Nf-kappab: A key role in inflammatory diseases. J Clin Invest. 2001;107:7-11

264 265

Li Q, Verma IM. Nf-kappab regulation in the immune system. Nat Rev Immunol.

Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nature

Reviews Cancer. 2006;6:493 9.

Amin MA, Matsunaga S, Uchiyama S, Fukui K. Depletion of nucleophosmin leads to

268

distortion

269

2008;415:345-351

270

10.

271 272

of

nucleolar

and

nuclear

structures

in

hela cells.

Biochem J.

Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: A possible therapeutic target in hematological diseases. Oncogene. 2011;30:2595-2609

11.

Naoe T, Suzuki T, Kiyoi H, Urano T. Nucleophosmin: A versatile molecule associated 15

273 274

with hematological malignancies. Cancer Sci. 2006;97:963-969 12.

275 276

Werner MT, Zhao C, Zhang Q, Wasik MA. Nucleophosmin-anaplastic lymphoma kinase (npm-alk): The ultimate oncogene and therapeutic target. Blood. 2016;129:823

13.

Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci P-G, Eilers M. A

277

ribosomal protein l23-nucleophosmin circuit coordinates miz1 function with cell growth.

278

Nature Cell Biology. 2008;10:1051

279

14.

Leotoing L, Meunier L, Manin M, Mauduit C, Decaussin M, Verrijdt G, Claessens F,

280

Benahmed M, Veyssiere G, Morel L, Beaudoin C. Influence of nucleophosmin/b23 on

281

DNA binding and transcriptional activity of the androgen receptor in prostate cancer

282

cell. Oncogene. 2008;27:2858-2867

283

15.

Murano K, Okuwaki M, Hisaoka M, Nagata K. Transcription regulation of the rrna gene

284

by a multifunctional nucleolar protein, b23/nucleophosmin, through its histone

285

chaperone activity. Mol Cell Biol. 2008;28:3114-3126

286

16.

Dhar SK, Lynn BC, Daosukho C, St Clair DK. Identification of nucleophosmin as an

287

nf-kappab co-activator for the induction of the human sod2 gene. J Biol Chem.

288

2004;279:28209-28219

289

17.

Liu H, Tan BC, Tseng KH, Chuang CP, Yeh CW, Chen KD, Lee SC, Yung BY.

290

Nucleophosmin acts as a novel ap2alpha-binding transcriptional corepressor during

291

cell differentiation. EMBO Rep. 2007;8:394-400

292

18.

Senthong V, Li XS, Hudec T, Coughlin J, Wu Y, Levison B, Wang Z, Hazen SL, Tang

293

WH. Plasma trimethylamine n-oxide, a gut microbe-generated phosphatidylcholine

294

metabolite, is associated with atherosclerotic burden. J Am Coll Cardiol. 16

295 296

2016;67:2620-2628 19.

Das S, Reddy MA, Senapati P, Stapleton K, Lanting L, Wang M, Amaram V, Ganguly

297

R, Zhang LX, Devaraj S, Schones DE, Natarajan R. Diabetes mellitus-induced long

298

noncoding rna dnm3os regulates macrophage functions and inflammation via nuclear

299

mechanisms. Arteriosclerosis Thrombosis and Vascular Biology. 2018;38:1806-1820

300

20.

Zhao TC, Taher MM, Valerie KC, Kukreja RC. P38 triggers late preconditioning

301

elicited by anisomycin in heart: Involvement of nf-kappab and inos. Circ Res.

302

2001;89:915-922

303

21.

Boyle EM, Jr., Kovacich JC, Canty TG, Jr., Morgan EN, Chi E, Verrier ED, Pohlman

304

TH. Inhibition of nuclear factor-kappa b nuclear localization reduces human e-selectin

305

expression and the systemic inflammatory response. Circulation. 1998;98:II282-288

306

22.

Liu SF, Ye X, Malik AB. Inhibition of nf-kappab activation by pyrrolidine

307

dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation.

308

1999;100:1330-1337

309

23.

Gambi G, Di Simone E, Basso V, Ricci L, Wang R, Verma A, Elemento O, Ponzoni M,

310

Inghirami G, Icardi L, Mondino A. The transcriptional regulator sin3a contributes to the

311

oncogenic potential of stat3. Cancer research. 2019;79:3076-3087

312

24.

Avitabile D, Bailey B, Cottage CT, Sundararaman B, Joyo A, McGregor M, Gude N,

313

Truffa S, Zarrabi A, Konstandin M, Khan M, Mohsin S, Volkers M, Toko H, Mason M,

314

Cheng Z, Din S, Alvarez R, Jr., Fischer K, Sussman MA. Nucleolar stress is an early

315

response to myocardial damage involving nucleolar proteins nucleostemin and

316

nucleophosmin. Proc Natl Acad Sci U S A. 2011;108:6145-6150 17

317

25.

Philip-Couderc P, Smih F, Pelat M, Vidal C, Verwaerde P, Pathak A, Buys S, Galinier

318

M, Senard JM, Rouet P. Cardiac transcriptome analysis in obesity-related

319

hypertension. Hypertension. 2003;41:414-421

320

26.

321 322

Csiszar A, Wang M, Lakatta EG, Ungvari Z. Inflammation and endothelial dysfunction during aging: Role of nf-kappab. J Appl Physiol (1985). 2008;105:1333-1341

27.

Kinumi T, Ogawa Y, Kimata J, Saito Y, Yoshida Y, Niki E. Proteomic characterization

323

of oxidative dysfunction in human umbilical vein endothelial cells (huvec) induced by

324

exposure to oxidized ldl. Free Radic Res. 2005;39:1335-1344

325

28.

Zwakenberg SR, van der Schouw YT, Vermeer C, Pasterkamp G, den Ruijter HM,

326

Beulens JWJ. Matrix gla protein, plaque stability, and cardiovascular events in

327

patients with severe atherosclerotic disease. Cardiology. 2018;141:32-36

328

29.

Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O.

329

Atherosclerotic plaque destabilization: Mechanisms, models, and therapeutic

330

strategies. Circ Res. 2014;114:214-226

331

30.

Ding Y, Zhang M, Zhang W, Lu Q, Cai Z, Song P, Okon IS, Xiao L, Zou MH.

332

Amp-activated protein kinase alpha 2 deletion induces vsmc phenotypic switching and

333

reduces

334

2016;119:718-730

335

31.

features

of

atherosclerotic

plaque

stability.

Circulation

research.

Cui XB, Luan JN, Dong K, Chen S, Wang Y, Watford WT, Chen SY. Rgc-32 (response

336

gene to complement 32) deficiency protects endothelial cells from inflammation and

337

attenuates atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology.

338

2018;38:e36-e47 18

339

32.

Horio E, Kadomatsu T, Miyata K, Arai Y, Hosokawa K, Doi Y, Ninomiya T, Horiguchi H,

340

Endo M, Tabata M, Tazume H, Tian Z, Takahashi O, Terada K, Takeya M, Hao H,

341

Hirose N, Minami T, Suda T, Kiyohara Y, Ogawa H, Kaikita K, Oike Y. Role of

342

endothelial cell-derived angptl2 in vascular inflammation leading to endothelial

343

dysfunction and atherosclerosis progression. Arteriosclerosis, thrombosis, and

344

vascular biology. 2014;34:790-800

345

33.

Daugherty A, Tall AR, Daemen M, Falk E, Fisher EA, Garcia-Cardena G, Lusis AJ,

346

Owens AP, 3rd, Rosenfeld ME, Virmani R. Recommendation on design, execution,

347

and reporting of animal atherosclerosis studies: A scientific statement from the

348

american heart association. Arterioscler Thromb Vasc Biol. 2017;37:e131-e157

349

34.

Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS, Smith JD. Consideration of

350

sex differences in design and reporting of experimental arterial pathology

351

studies-statement from atvb council. Arterioscler Thromb Vasc Biol. 2018;38:292-303

352 353

35.

Braun M, Pietsch P, Schror K, Baumann G, Felix SB. Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res. 1999;41:395-401

19

354

Figure legends

355

Figure 1. NPM was enriched in human atherosclerotic plaques. (A) Quantitative Real-time

356

PCR showed that NPM mRNA expression was markedly increased in human carotid

357

atherosclerotic plaques compared with healthy arteries, n=12, **P < 0.01 vs normal. (B)

358

Immunoblots showed that NPM protein level in atherosclerotic plaques was significantly higher

359

than that in control, n=6, ***P < 0.001 vs normal. (C) Representative images of dual

360

immunofluorescent staining showed that NPM was predominantly expressed in endothelial cells.

361

For co-localization analysis, sections were dual-stained for NPM (green) and CD31 (red,

362

endothelial marker), a-SMA (red, smooth muscle cell marker), or CD68 (red, macrophage marker).

363

DAPI was used for nucleus staining (blue). NPM and endothelial cell-specific marker

364

double-positive cells were indicated by arrows.

365

Figure 2. Inhibition of NPM attenuated endothelial dysfunction and atherosclerosis in

366

western diet-fed ApoE-/-mice. (A and B) Recombinant adenovirus (Ad-shNPM) significantly

367

decreased the protein and mRNA level of NPM in the murine vessel, n=3, **P<0.01 vs shNC. (C)

368

ApoE-/- mice fed a chow diet (upper) or a western diet (lower) were injected with Ad-shNC or

369

Ad-shNPM. Oil Red O staining showed that Ad-shNPM decreased lesion area at aortic sinus in

370

western diet-fed ApoE-/- mice, n=6, **P<0.01 vs shNC. (D) Representative images of Oil Red O

371

staining in the whole aorta. Quantification analysis showed that Ad-shNPM markedly reduced

372

atherosclerotic plaque formation in western diet-fed ApoE-/- mice, n=6, ***P<0.001 vs shNC. (E)

373

Representative images of aortic sinus sections stained with Hematoxylin-eosin (HE), Masson’s

374

trichrome (Masson), elastica van Gieson (EVG) and immunohistochemical staining for α-SMA

375

and CD68. Circular regions mark the necrotic core area. The black arrows indicate α-SMA 20

376

staining panels where fibrous caps were formed, which can be used for calculating the thickness of

377

the fibrous caps. The white arrows in EVG staining panels indicate the rupture of elastic fibers of

378

tunica media. Histological quantification analysis showed that Ad-shNPM changed the

379

pathological features of atherosclerotic lesions compared with Ad-shNC, n=6, *P<0.05, **P<

380

0.01, ***P<0.001 vs shNC. (F) Western blot was performed to detect the protein levels of

381

ICAM-1, VCAM-1, E-selectin, total and phosphorylated NF-κB p65 subunit in the vessel tissues

382

of ApoE-/- mice. Densitometric analysis showed that Ad-shNPM suppressed NF-κB p65

383

phosphorylation and decreased the protein level of VCAM-1, ICAM-1, E-selectin, n=6, *P<0.05,

384

**P<0.01 vs shNC. Data are expressed as mean ± SD, “n. s.” means no statistical significance.

385

Figure 3. Knockdown of NPM suppressed the inflammatory responses in HUVECs. (A)

386

Real-time PCR showed that knockdown of NPM by siRNA decreased mRNA expression levels of

387

inflammatory chemokines, adhesion molecules and procoagulant factors in HUVECs treated with

388

500 µmol/L palmitic acid (PA) for 24 h, n=3, *P<0.05, **P<0.01 vs scramble siRNA. (B)

389

Knockdown of NPM with siRNA notably reduced the levels of IL-1β, IL-6 and TNFα in the

390

supernatants of HUVECs treated with 500 µmol/L PA for 24 h, n=5, *P<0.05, **P<0.01, ***P

391

<0.001 vs scramble siRNA. (C) Immunoblot for ICAM-1, VCAM-1, E-selectin and P-selectin in

392

HUVECs showed that NPM knockdown suppressed the expression of all these adhesion

393

molecules, n=3, *P<0.05 vs scramble siRNA. (D) NPM knockdown significantly reduced the

394

number of peripheral blood monocytes attached to PA-activated endothelial cell monolayers in the

395

adhesion assay, n=3, *P<0.05, **P<0.01 vs scramble siRNA. Data are expressed as mean ± SD,

396

“n. s.” means no statistical significance.

397

Figure 4. NPM physically interacted with NF-κ κB p65 subunit and promoted its activation. (A) 21

398

Immunoblots analysis of p65, Iκbα and their phosphorylated protein level in total HUVECs

399

protein after stimulated with 500 µmol/L PA for 1h, and NPM siRNA significantly decreased the

400

ratio of p-p65/p65 and p-Iκbα/Iκbα, n=3, *P<0.05 vs scramble siRNA. (B) Immunoblots of p65

401

protein level in nuclear extract and cytoplasmic extract showed that PA increased and decreased

402

the expression of p65 in nucleus as well as in cytoplasm respectively, which were both inhibited

403

by NPM siRNA. n=3, *P<0.05 vs scramble siRNA. (C) Representative immunofluorescent

404

staining against p65 (green) showed that NPM knockdown inhibited p65 intranuclear translocation

405

induced by PA. The nucleus was stained with DAPI (blue). (D) Immunoblots for NPM and NF-κB

406

p65 after immunoprecipitation with anti-p65 antibody, anti-NPM antibody demonstrated physical

407

binding of NPM and NF-κB. PA stimulation strengthened their interaction with each other in

408

HUVECs. (E) Luciferase assay was used to measure NF-κB promoter activity. Luciferase reporter

409

construct containing the promoter of p65 was transfected with an internal control plasmid pRL-TK

410

into HEK293 cells. PA treatment and NPM overexpression significantly augmented the promoter

411

activity of NF-κB p65, which could be inhibited by either NPM siRNA or NF-κB inhibitor PDTC,

412

n=3, **P<0.01. Data are expressed as mean ± SD, “n. s.” means no statistical significance.

413

Figure 5. NPM enhanced the transcriptional activity of NF-κ κB to its downstream target

414

genes. (A) Luciferase reporter constructs containing promoters of ICAM-1, VCAM-1, E-selectin

415

and P-selectin were co-transfected with an internal control plasmid pRL-TK into HEK293 cells.

416

PA treatment and NPM overexpression significantly augmented the promoter activity of these

417

adhesion molecules (excluding ICAM-1), which could also be inhibited by NPM siRNA or NF-κB

418

inhibitor PDTC, n=3, **P<0.01, ***P<0.001. (B) Chromatin immunoprecipitation (ChIP) assay

419

was performed in cultured HUVECs using ChIP standard p65 antibody. IgG acted as negative 22

420

control. Percentage of amplified signals from IP chromatin to amplified input signals obtained

421

from the same sample indicated that NPM overexpression could significantly enhance NF-κB p65

422

binding to its downstream gene promoters, including IL-1β, IL-6, ICAM-1 and E-selectin, n=3, *P

423

<0.05, **P<0.01 vs IgG group. Data are expressed as mean ± SD, “n. s.” means no statistical

424

significance.

425

Figure 6. Graphical abstract of how nucleophospmin contributed the progression of

426

atherosclerosis. Risk factors induced the expression of nucleophosmin, which subsequently increased

427

the phosphorylation of NF-κB p65 subunit and promoted its translocation to nucleus, resulting

428

production of inflammatory cytokines and adhesion molecules. Vascular inflammation and endothelial

429

dysfunction aggravated atherosclerosis progression.

23